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Abstract
Microdeletions of chromosomal region 2q23.1 that disrupt MBD5 contribute to a spectrum of 
neurodevelopmental phenotypes, however the impact of this locus in human psychopathology has 
not been described. To characterize the structural variation landscape of MBD5 disruptions and the 
associated psychopathology, 22 individuals with genomic disruption of MBD5 (translocation, 
point mutation, and deletion) were identified through whole-genome sequencing or cytogenomic 
microarray at 11 molecular diagnostic centers. The genomic impact ranged from a single base pair 
to 5.4 Mb. Parents were available for 11 cases, all of which confirmed the rearrangement arose de 
novo. Phenotypes were largely indistinguishable between patients with full-segment 2q23.1 
deletions and those with intragenic MBD5 rearrangements, including alterations confined entirely 
to the 5′UTR, confirming the critical impact of non-coding sequence at this locus. We found 
heterogeneous, multi-system pathogenic effects of MBD5 disruption and characterized the 
associated spectrum of psychopathology, which includes sensory integration disorder, anxiety, 
self-hugging, bipolar disorder and others. Importantly, unique features of the oldest assessed 
patient were early-onset dementia and behavioral regression. Analyses also revealed phenotypes 
that distinguish MBD5 disruptions from seven well-established syndromes with significant 
diagnostic overlap. This study indicates that haploinsufficiency of MBD5 causes diverse 
phenotypes, yields insight into the spectrum of resulting neurodevelopmental and behavioral 
psychopathology, and provides clinical context for interpretation of MBD5 structural variations. 
Empirical evidence also suggests that disruption of non-coding MBD5 regulatory regions is 
sufficient for clinical manifestation, highlighting the limitations of exon-focused assessments. 
These results suggest an ongoing perturbation of neurological function throughout the lifespan, 
including risks for neurobehavioral regression and early-onset dementia.
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Introduction
The increasing resolution of genomic technologies, including cytogenomic microarrays and 
next-generation sequencing, has led to remarkable advances in our understanding of the 
highly heterogeneous genetic etiology of neurodevelopmental conditions such as autism 
spectrum disorders (ASD). Among the largest known genetic risk factors contributing to 
ASD are recurrent structural variations such as chromosomal microdeletions and 
microduplications. However, interpretation of the associated clinical outcomes is 
complicated by the varying sizes of these dosage imbalances which typically disrupt many 
genes. For example, the 16p11.2 microdeletion and microduplication syndromes are 
associated with a spectrum of features including ASD, schizophrenia, obesity, dysmorphic 
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characteristics, and numerous other neuropsychiatric and behavioral disorders.1, 2 Only a 
small number of recurrent chromosomal microdeletion syndromes have a single known 
contributing gene, such as SATB2 in 2q33.13, 4 and EHMT1 in 9q34.34, 5. The localization of 
these contributing loci provides a route to understanding pathogenic mechanisms as well as 
deeply characterizing associated phenotypic features of these typically heterogeneous and 
complex syndromes. In the current study, we perform extensive phenotypic analyses of the 
diverse psychopathology associated with a single necessary and sufficient causal locus in the 
chromosome 2q23.1 microdeletion syndrome and describe the clinical features that overlap 
with multiple known syndromes.
The pathogenesis of 2q23.1 microdeletion syndrome was recently defined by Talkowski et 
al6 and others7–15 to be due to haploinsufficiency of a single gene, MBD5 (methyl-CpG-
binding domain protein 5), through characterization of the minimal region of overlap from 
non-recurrent genomic alterations in a cohort of 65 cases with chromosomal deletions or 
translocations. The mRNA isoform 1 of MBD5 comprises 15 exons with exons 1–5 forming 
the non-translated 5′UTR. Monoallelic expression of this locus was found to be highly 
penetrant as both partial and complete deletions of MBD5 involving coding and/or non-
translated exons resulted in diverse neurodevelopmental phenotypes including ASD, 
intellectual disability, and seizures. In addition, no alterations of MBD5 exons were 
observed in 7,878 controls or in the Database of Genomic Variants (DGV).6
The association of MBD5 disruption with ASD and other neurobehavioral features is 
supported by its expression in the brain and the suggested function of its methyl-CpG-
binding domain in heterochromatin and epigenetic regulation.16, 17 In addition, sequencing 
of the MBD5 coding region identified a missense mutation (p.79Gly>Glu) in this 
functionally critical domain that was significantly overrepresented in 747 ASD patients 
compared to 2,043 individuals from an exome sequencing study of patients with disorders of 
the heart, lungs and blood (NHLBI Exome Sequencing Project; initial p = 0.012, OR = 5.5).6 
Notably, the recent completion and revised variant calling in the final exome sequencing 
analyses of this mutation provides a more robust estimate of its association and effect size in 
ASD (p = 0.0039, OR = 5.2).18 The methyl-CpG-binding domain is also shared with 
MECP2, a causal locus for Rett syndrome. Clinical features associated with MBD5 deletions 
have considerable overlap with Rett syndrome and can also masquerade as Smith-Magenis 
(SMS), Cornelia de Lange (CdLS), Angelman (AS), Prader-Willi (PWS), Kleefstra, and 
Pitt-Hopkins (PTHS) syndromes.
We report here phenotypic characterization of 22 individuals with MBD5 structural 
alterations collected through a multi-institution collaboration, revealing a complex clinical 
syndrome that involves a diverse range of neurodevelopmental features with variable 
severity. A significant inclusion in this cohort is the oldest assessed MBD5 deletion patient 
who provides important confirmatory evidence that behavioral regression is a potential 
outcome. Interestingly, a subset of these patients with disruptions confined to the non-
coding region of MBD5 manifest a similar spectrum of clinical features as those with coding 
region rearrangements, confirming a pathogenic role for non-coding regulatory domains. We 
further identify considerable phenotypic overlap between MBD5 disruptions and other 
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known diagnoses, and provide clinical context for syndrome differentiation with an 
emphasis on neurobehavioral considerations.
Methods
Subjects
Diagnostic screening of postnatal peripheral blood specimens from 17,477 consecutive 
patients tested in the Mayo Clinic Cytogenetics Laboratory from 2008–2012 using either the 
4×44K or 4×180K oligonucleotide-based whole-genome cytogenomic microarray (Agilent 
Technologies, Santa Clara, CA) identified eight deletions spanning genomic segments 
including MBD5 (Cases 1–8), six of which were of sufficient size for detection (>100 kb) 
and had cells available for confirmation by fluorescence in situ hybridization (FISH). 
Clinical phenotypic information was obtained from medical records following a Mayo 
Clinic IRB-approved protocol. A multi-institution collaboration of clinical diagnostic 
laboratories resulted in inclusion of additional patients not previously published from the 
Greenwood Genetic Center (Cases 9–12), Pathology Associates Medical Laboratories 
(Cases 13–14), Virginia Commonwealth University (Case 15), Fullerton Genetics Center 
(Case 16), and Boston Children’s Hospital (Case 17) that were identified with different 
cytogenomic microarray platforms. Phenotypes were further considered in the analysis of 
two MBD5 deletion cases reported by Motobayashi et al19 (Motobayashi/Case 18) and Noh 
et al20 (Noh/Case 19) as well an intragenic frameshift mutation c.150del or p.Thr52Hisfs*31 
described by Kleefstra et al5 (Kleefstra/Case 20) and an intragenic indel of -TC at position 
148,942,435 in hg18 of exon 9 described by O’Roak et al21 (O’Roak/Case 21), all of which 
were published after the Talkowski et al study6. The final patient, DGAP235 (Case 22), was 
enrolled in the Developmental Genome Anatomy Project (DGAP; www.dgap/harvard.edu) 
based on karyotypic detection of a de novo, balanced translocation 46,XY,t(2;5)(q22;q22), 
which was found to disrupt MBD5 by massively parallel paired-end sequencing; this case 
was independent of two previously published translocations targeting MBD5.6
Genetic analysis of translocation case
Whole genome sequencing was performed using large-insert fragments in a mate-pair 
method that was previously optimized and applied to cases with abnormal 
karyotypes.4, 22, 23 Sequencing paired-ends of fragments separated by 2,000 bases in 
genomic distance enabled high coverage of mapped inserts in a genome-wide manner with 
minimal individual nucleotide coverage required. In brief, genomic DNA was randomly 
sheared and size selected for 2 kb fragments. A cap adaptor containing an EcoP15I 
restriction site was ligated to the fragment ends and circularized with an internal adaptor 
containing a subject specific bar code and a single biotinylated thymine. The circularized 
fragments were restriction digested, junction fragments were isolated by binding the 
biotinylated adaptor to streptavidin beads, and an Illumina library was prepared directly on 
the beads. Multiplexed paired-end 25 cycle sequencing was performed on an Illumina HiSeq 
2000 and 45.7% of all reads corresponded to DGAP235 (87,079,316 reads pairs). Quality 
control was assessed using FASTQC (Babraham Bioinformatics) followed by distributed 
parallel alignment of FASTQ read data to the human genome reference hg19 using BWA 
0.5.924, merging of aligned BAM files with SAMtools 0.1.1824, and coordinate and name-
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sorting of aligned read-pairs using Picard Tools 1.5.8 (http://picard.sourceforge.net). A 
single-linkage clustering of anomalous read-pairs was competed with subsequent filtering of 
clusters based on size, mapping quality, uniqueness, and presence in a previous database of 
whole genome sequencing samples from a neurodevelopmental cohort4 using a custom 
pipeline developed in C++ (BamStat) and MATLAB (Mathworks). The average mapped 
insert was 1,862 bp (standard deviation = 332 bp) and 94.1% of all reads aligned, yielding 
an average coverage of mappable inserts of approximately 39.2X (Supplementary Figures 
S1). See Supplementary Table S1 and Supplementary Results for library metrics, alignment 
information and bioinformatics analysis.
Phenotypic analysis
The developmental history and neurological, behavioral, and physical characteristics of the 
new patients were assembled. In addition, the original phenotypic data from the 65 cases 
reported by Talkowski et al6 were examined. Age-dependent characteristics were considered 
relative to developmental stage. Individuals were considered to have “autistic-like 
symptoms” if autistic-like behaviors were specifically reported or a diagnosis of pervasive 
developmental disorder (PDD-NOS) was given. Phenotypic features were classified as 
present, absent, or not evaluated, and were reported in Table 3 only if present in more than 
one individual.
The clinical features of the new cohort (n = 22) were assessed for both overlap with and 
divergence from those cases in the published original cohort that had phenotypic data 
available (n = 48) to enable a more comprehensive phenotypic profile associated with MBD5 
disruption. A list of the 48 cases analyzed from the original cohort of Talkowski et al6 is 
provided in the Supplementary Results. The phenotypic spectrum of the combined original 
and new MBD5 disruptions (n = 70) was then compared and contrasted to well-established 
syndromes with diagnostic overlap (SMS, CdLS, AS, PWS, Rett, Kleefstra and PTHS). In 
each of these evaluations, cases were grouped by genotype, i.e. intragenic MBD5 disruptions 
versus overlapping 2q23.1 deletions.
Results
Identification and molecular characterization of MBD5 disruption cases
The frequency of MBD5 deletion was estimated to be 0.05% based on the identification of 8 
cases out of 17 477 consecutive Mayo Clinic peripheral blood samples submitted for clinical 
testing by cytogenomic microarray. These 8 deletions, along with 10 cases from 
collaborators and 4 cases identified recently in the literature, define a new cohort that is 
independent of the subjects in Talkowski et al6. The new cohort (n = 22) includes one 
frameshift mutation, one indel mutation, one inverted translocation directly disrupting 
MBD5, three intragenic MBD5 deletions, and 16 larger deletions. The rearrangements arose 
de novo in all cases for which parental testing was available (n = 11). However, two cases 
without parental genetic or phenotypic information involve brothers with similar deletions, 
suggesting likely parental inheritance or gonadal mosaicism. No bias in gender or age of 
diagnosis was observed in the 13 males and nine females ranging in age from two weeks to 
69 years. The disrupted region varied from a single base pair point mutation to a 5.4 Mb 
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microdeletion, with 17 of the alterations being no more than 1.1 Mb (Figure 1a). Five of 
these alterations are within MBD5, all but one of which is confined entirely to the non-
coding 5′UTR. In addition, Case 2 is a high percentage mosaic with the deletion present in 
28/30 metaphases and 77.5% of interphase nuclei from a cultured specimen as well as 
81.0% of interphase nuclei from a direct preparation.
Case 22 harbored a de novo translocation between chromosomes 2 and 5 that was balanced 
at karyotypic resolution. Whole-genome sequencing by large-insert jumping libraries 
revealed direct disruption of MBD5 at the breakpoint on chromosome 2. The orientation of a 
small subset of reads relative to the reference sequence also supported the presence of a 
small local inversion at the chromosome 5 breakpoint on the der(2) chromosome, suggesting 
a translocation with an accompanying inversion (Figure 1b). We previously discovered that 
such microinversions are a pervasive feature of karyotypically balanced translocations.22 
Capillary sequencing confirmed the translocation breakpoints on both derivative 
chromosomes and the presence of a 169 bp microinversion of chromosome 5 on the der(2). 
The chromosome 2 breakpoints (der(2):148,732,432; der(5):148,733,228 in human genome 
build hg18) directly disrupt the 5′ non-coding region of MBD5 that was previously shown to 
be interrupted in two independent translocations sequenced in Talkowski et al6. In sum, a 
total genomic imbalance of 795 bp was observed at the der(5) breakpoint (including both 
deleted sequence and duplication of microhomology), and the der(2) translocation and 
inversion events resulted in 41 bp of deleted sequence. The chromosome 5 breakpoint 
occurred in an intergenic region without annotated coding sequence within a 500 kb window 
of the breakpoint. Sequencing thus revised the interpretation of the karyotype from 
46,XY,t(2;5)(q22;q22) to 46,XY,der(2)t(2;5)(q23.1;q23.1)inv(5)(q23.1q23.1),der(5)t(2;5)
(q23.1;q23.1)dn. See Supplementary Table S2 for complete breakpoint information.
In the original cohort described by Talkowski et al6 there were 12 intragenic MBD5 
deletions, two other translocations disrupting the same untranslated region of MBD5 as the 
present case, and 41 larger 2q23.1 microdeletions encompassing MBD5 and additional genes 
ranging in size from 38 kb to 19.3 Mb. After removal of the Talkowski et al cases without 
phenotypic information, the remaining 48 individuals were added to the 22 new cases for 
analysis. This combined cohort (n = 70) involved three translocations, one point mutation, 
one indel, and 65 deletions; 16 are intragenic MBD5 alterations, all but one of which are 
confined to the 5′UTR. The following analyses are derived from the phenotypic features of 
these 70 individuals.
MBD5 disruption is associated with neurodevelopmental features and clinical variation 
including behavioral regression
Comparison of the original raw data from the MBD5 disruption cases in Talkowski et al6 to 
a new cohort of 22 cases demonstrated an independent confirmation of substantial genetic 
and phenotype overlap between the two groups. Combined assessment of these cohorts 
showed that MBD5 disruption has a multi-system effect, leading to behavioral, growth/
endocrine, craniofacial, skeletal, gastrointestinal, heart, urogenital and central nervous 
system anomalies.
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The phenotypes are largely indistinguishable between intragenic MBD5 and larger deletions, 
whether considering neurodevelopmental and behavioral abnormalities specifically or all 
other features (Table 1). However, a small subset of the characteristics may have resulted 
from loss of neighboring genes. This is suggested by features that were confined to larger 
deletion cases in both the new cohort and separately in the original cohort6 that were 
assessed in at least 4 patients, specifically bruxism, hyperphagia, ataxia, obesity, 
brachycephaly, metopic ridging, optic nerve hypoplasia, strabismus, coarse facies, wide 
mouth, brachydactyly and hypoplastic genitalia. It is of note that only 2 of these twelve 
features are neurodevelopmental or psychiatric in origin, which further implicates MBD5 as 
the causative gene for the majority of such phenotypes. Additional features potentially 
arising from genes near MBD5 are demonstrated in the combined cohort analysis (Table 1). 
However, definitive genotype/phenotype correlations are challenging due to the relative 
rarity of intragenic MBD5 disruptions (n = 16) compared to 2q23.1 microdeletions (n = 54), 
warranting further consideration in even larger cohorts.
Potential novel behavioral features linked with MBD5 disruption are suggested in the new 
cohort including sensory integration disorder, anxiety, bipolar disorder and self-hugging, as 
well as a number of physical anomalies (Table 2). The associations of MBD5 disruption with 
optic nerve hypoplasia and with social withdrawal were also potentially confirmed through 
observation of a second affected patient (Case 3 and Case 21, respectively). The new cohort 
further includes the oldest assessed MBD5 disruption patient, a 44-year old man who had the 
novel features of early-onset dementia and cataracts (Case 3). Importantly, he demonstrated 
behavioral regression with worsening skin picking and obsessive-compulsive tendencies. 
Regression of motor and verbal skills was also noted in a second case in the new cohort 
(Case 19).20
Phenotypic presentation of MBD5 disruption overlaps with known syndromes
We analyzed extensive phenotypic data in a large cohort of subjects with MBD5 disruptions 
to understand the consequences of multiple mutational mechanisms impacting transcription 
of this gene and to provide an assessment algorithm for clinicians to identify affected 
patients. However, devising an appropriate testing strategy presents a significant challenge 
due to substantial heterogeneity in both the type and severity of MBD5-related phenotypes 
which span cognitive, behavioral and physical domains. Moreover, MBD5 disruption is a 
potent masquerader, resulting in a number of clinical features previously thought to be 
unique to other syndromes. Based on our analyses, it is clear that a first-tier diagnostic 
cytogenomic microarray test will aid in the partitioning of subjects into gene-specific 
disorders characterized by dosage imbalance. Such a recommendation would be consistent 
with recent guidelines.25, 26 Absence of detectable dosage imbalance will then require 
clinicians to decide if karyotype or targeted gene-specific testing, such as sequencing for 
intragenic point mutations, small deletions or duplications, is appropriate based on the 
phenotypic gestalt. Of note, although whole exome sequencing is moving towards replacing 
cytogenomic arrays and gene or gene panel sequencing, targeted gene analysis could still 
have an important role in the future as UTR variants, including those in multiple cases in the 
current study, might not otherwise be detected.
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To aid in determining the next diagnostic step in the absence of a detectable dosage 
imbalance, we present expansion of the clinical heterogeneity associated with MBD5 
disruption, as well as the distinguishing phenotypes or constellations of anomalies which 
would suggest additional diagnostic testing for MBD5 versus targeting a classic syndrome 
with overlapping features including SMS27–32, PWS33–38, AS39, 40, CdLS41–44, Rett45–47, 
Kleefstra48–50, or PTHS51–53. Thus, the phenotypes in the combined cohort separated by 
intragenic MBD5 versus larger 2q23.1 deletions that occurred in two or more cases were 
compared to those of other syndromes considered in the differential diagnosis (Table 3).
Neurodevelopmental and behavioral characteristics common to all of these syndromes 
include autistic-like actions, intellectual disability, developmental delay, speech delay, 
motor delay, hypotonia, sleep disturbances and seizures. There are also features confined 
solely to each of the syndromes in the differential diagnosis as detailed in the Supplementary 
Results. Although single characteristics can be helpful, the phenotypic diversity noted with 
MBD5 disruptions remains a diagnostic challenge, as illustrated in the divergence of facial 
dysmorphism in MBD5 deletion cases, ranging from isolated ear anomalies to multiple 
atypical characteristics (Figure 2). A clear understanding of how the breadth of phenotypes 
compares and contrasts for these multiple diagnoses is required. The differentiating and 
overlapping neurodevelopmental, behavioral, and other features presented in Table 3 are 
further described in detail for each syndrome in the Supplementary Results.
Discussion
Deletions encompassing MBD5 are highly penetrant and result in a broad phenotypic 
spectrum that includes many neurodevelopmental and psychiatric traits. Our analyses of 22 
cases with extensive clinical information confirm the phenotypes previously described in an 
independent cohort of 65 subjects described in Talkowski et al6 and define the significant 
psychopathology associated with MBD5 disruptions. When combined, these data 
demonstrate similar phenotypic traits between individuals with intragenic MBD5 alterations 
and larger 2q23.1 microdeletions, consistent with MBD5 being the necessary and sufficient 
pathogenic target in 2q21.3 microdeletion syndrome. The new cohort further expands the 
potential phenotypic spectrum to include the behavioral characteristics of sensory 
integration disorder, anxiety, bipolar disorder, and self-hugging, as well as the physical 
anomalies polydactyly, skin tags, diaphragmatic eventration, ventricular septal defect 
(VSD), spina bifida, cutis marmorata, flat occiput and short neck. The associations with 
optic nerve hypoplasia and with social withdrawal, each observed in a single patient in the 
original cohort6, were also demonstrated by independent cases in this new cohort.
The potential for MBD5 to perturb neurological function throughout life was demonstrated 
by the oldest assessed MBD5 deletion patient at 44 years of age (Case 3). Such a delayed 
diagnosis is consistent with the difficulty in clinically identifying MBD5 deletions and 
suggests potential longevity for affected individuals; a normal lifespan is further implied by 
a 69 year old male (O’Roak/Case 21), although his associated features are only known 
through 4 years of age. The 44 year old patient had early-onset dementia, cataracts and 
behavioral regression with a significant increase in skin picking and obsessive-compulsive 
activities. He thus represents the third case for which regression has been documented and 
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the first case with early-onset dementia. Regression also occurred in a second patient 
included within the new cohort (Noh/Case 19), a 2 year old girl with a 300 kb deletion 
overlapping two genes at 2q23.1. This child walked independently at 28 months of age but 
an examination at four years showed that she had lost a subset of her vocabulary and the 
ability to walk, standing only with support.20 Another case of developmental regression was 
previously noted to occur suddenly at six years of age in a girl with a de novo approximately 
4 MB deletion involving 15 genes at 2q23.1-q23.3. This child had progressive difficulties 
with fine motor skills and balance, worsening behavior, and loss of the ability to draw lines 
and circles.9 It is of note that this child was originally tested for Rett and Angelman 
syndromes with normal results before the MBD5 deletion was identified. These results merit 
careful evaluation of future cases for developmental and behavioral regression and 
emphasize the recommendation of cytogenomic microrarray as a first-tier test for all such 
cases.
Many features found in MBD5 deletions such as intellectual disability, motor and speech 
delays, sleep disturbances, microcephaly, and seizures are non-specific and commonly found 
in multiple genetic syndromes. A more specific spectrum of behavioral and other 
phenotypes in individuals with MBD5 disruptions may be diagnostically useful, although it 
remains challenging to differentiate from the profiles in other syndromes including SMS, 
CdLS, AS, PWS, Rett, Kleefstra, and PTHS. In fact, many patients with MBD5 deletions 
previously reported in the literature were referred for genetic testing for one or more of these 
disorders, all of which were negative, prior to cytogenomic microarray providing an 
accurate diagnosis; this is illustrated well in a study of 2q23.1 microdeletion syndrome 
patients (n = 11) who had normal test results for AS (n = 8), SMS (n = 5) and Rett (n = 4) 
syndrome.8 In the current cohort, the known additional testing included karyotype (n = 6), 
fragile X analysis (n = 6), RAI1 sequencing for SMS (n = 2), MECP2 and CDKL5 
sequencing for Rett syndrome (n = 1), methylation analysis and UBE3A sequencing for 
PWS/AS (n = 1), and TCF4 sequencing for PTHS (n = 1). It is of note that guidelines 
indicate fragile X testing should be performed for any patient with intellectual disability54, a 
feature also found in MBD5 disruption, although there is no overlap of more specific 
phenotypes between these two syndromes which suggests that they should be clinically 
distinguishable.
The ability of MBD5 deletions to manifest significant clinical heterogeneity that overlaps 
with previously defined syndromes in a highly penetrant manner confirms the advantage of 
using unbiased, high resolution genome-wide surveys such as cytogenomic microarrays 
when any of the above mentioned syndromes is suspected. However, cytogenomic 
microarrays do not detect balanced abnormalities or small pathogenic mutations, as occurred 
in cases 20 through 22, suggesting that implementation of whole-genome sequencing will 
also have a significant diagnostic impact and karyotyping may reveal additional balanced 
rearrangements. Our results further raise important issues about the current interpretation of 
variants of unknown significance and coding region-focused analyses such as exome 
sequencing as we found highly penetrant pathogenic rearrangements confined to the putative 
5′UTR of MBD5 (as in cases 5, 6, 16, 20 and 22) to be contributory towards diverse 
phenotypes. Therefore, a focused phenotypic annotation was undertaken in the current study 
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to complement the recent genetic characterization6 of MBD5 disruptions and to identify 
features that contrast with syndromes for which MBD5 can be mistaken. This may help 
determine an appropriate testing strategy and avoid unnecessary medical expenses.
In summary, careful phenotyping of patients with MBD5 disruptions confirms that 
abnormalities at this locus are highly penetrant risk factors for neurodevelopmental and 
other abnormalities. We also extend the associated clinical heterogeneity to a broad range of 
neuropsychiatric features including early-onset dementia, provide a differential diagnostic 
context, and suggest that this locus is potentially associated with risk for neurobehavioral 
regression.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Structural alterations disrupting MBD5. (a) UCSC genome browser (genome build hg18) 
demonstrating 22 cases of intragenic MBD5 and larger 2q23.1 disruptions (red bars) 
identified by cytogenomic microarray. MBD5 is at position 148,495,050–148,987,514 and 
contains 15 exons of which exons 1–5 are the non-coding 5′UTR and exons 6–15 are protein 
coding. Cases 5, 6, 16, 20 and 21 involve disruptions confined to the non-coding region of 
MBD5 and Case 22 is confined to the coding region of MBD5, while all other cases overlap 
at least one other gene. Asterisks (*) denote a single base pair change resulting in a 
frameshift mutation in Case 20, a two base pair deletion in Case 21, and the translocation 
breakpoint in Case 22. (b) Whole genome sequencing of Case 22 delineated that an 
apparently balanced translocation between chromosomes 2 and 5 directly disrupted MBD5 at 
2q23.1 and did not affect any annotated functional sequence on chromosome 5. A local 
microinversion of 169 bases was also detected at the breakpoint of the chromosome 5 
material on the der(2) chromosome. The GTG-banded idiograms depict the normal 
chromosomes 2 and 5 as well as the derivative chromosomes from the translocation. The 
breakpoint regions on the derivative chromosomes are expanded in the middle, providing 
genomic coordinates, cytogenetic bands, precise breakpoints (dotted red line), and 
surrounding nucleotide sequence of the junctions including microhomology (highlighted in 
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yellow) at the translocation and inversion breakpoints. The 5′ and 3′ non-coding UTR 
regions of the disrupted MBD5 transcript are highlighted in green, the translated region is 
highlighted in blue, and exons are denoted by rectangles.
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Clinical features associated with MBD5 disruption.
Patients with MBD5 deletions have a broad range of physical features both in type and 
severity. A, Case 4 (6 year 9 month old female) has a round face, midface hypoplasia, flat 
nose and thin upper lip, which along with ID/DD, hearing loss, and unusual behavior of self-
injury and altered sleep cycle, were highly suggestive of SMS. Cytogenomic microarray 
demonstrated a de novo deletion (153 kb) of the MBD5 5′ UTR while subsequent 
sequencing of the RAI1 gene associated with SMS was negative. B, Case 15 (7 year 9 month 
old male) has brachycephaly, midface hypoplasia, depressed nasal bridge, a thin and tented 
upper lip, open mouth and dental crowding. C, Case 12 (3 year old female) has dysmorphic 
facies with synophrys, slightly downslanting palpebral fissures, tented upper lip, depressed 
nasal bridge with an upturned nose and somewhat prominent ears with attached lobes as 
well as a low posterior hairline, right supernumerary nipple, short neck, short thumbs and 
fifth fingers, and mildly dysplastic fifth toenails. D, Case 8 (2 year old male) has an open 
mouth with downturned corners, a depressed nasal bridge, and an overfolded helix. E, Case 
11 (20 year old female) has a thin upper lip, a slightly smooth philtrum, mild epicanthal 
folds with slightly upslanting palpebral fissures and a prominent columella with a thickened 
nasal tip. F, Case 8 (14 year old male) has mildly prominent and overfolded ears with 
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thickened helices. G, Case 9 (12 year old male) is the brother of Case 8 and has similar 
atypical ears. H, Case 16 (7 year old male) has a thin upper lip, long philtrum, prominent 
nasal bridge, arched eyebrows, epicanthal folds and almond-shaped eyes.
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